Home About Us Management Product Pipeline Collaborators Contact Us
Menutext


Pipeline


Candidate & Indication
Developmental Stage
Pre-clinical
Toxicology
Phase 1
Phase 2
1a. PLAP; injection formulation to enhance cancer treatments by reducing muscle wasting and loss of body weight as well as promoting bone marrow regeneration from endogenous stem cells
Exit after Phase 1 or Phase 2
1b. PLAP; injection formulation to enhance regeneration of bone marrow from transplanted stem cells
Exit after Phase 1 or Phase 2
2. PLAP; oral formulation to treat metabolic syndrome and muscle wasting in obese/type 2 diabetic elderly patients
Exit after Phase 1
3. PLAP; skin formulation to promote diabetic wound healing
Develop fully
4. PLAP; skin formulation to treat inflammatory/infectious skin conditions (acne, shingles, herpes, psoriasis)
human proof of principle studies have already been done in all cases
Continue studies
5. PLAP; injection formulation to prevent type 3c diabetes
Continue studies